AZD4573

Name: AZD4573
Brand: MedChemExpress
SKU: HY-112088
Rating: 5.0 (14 reviews)

Cat. No.: HY-112088 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

AZD4573 is a potent and highly selective CDK9 inhibitor (IC₅₀ of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies.

For research use only. We do not sell to patients.

CAS No. : 2057509-72-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

14 Publications Citing Use of MCE AZD4573

Cell Proliferation/Viability Assay

RT-PCR

In Vivo Efficacy Study

: AZD4573 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. [Abstract]; qPCR data showing the expression levels of TC target genes after AZD4573 (300 nM) treatment.

: AZD4573 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. [Abstract]; AZD4573 (300 nM) displayed a significant reduction in TC nuclear immunofluorescence.

: AZD4573 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. [Abstract]; AZD4573 (300 nM) reduced TC levels by Immunoblotting.

: AZD4573 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jan 2;84(1):17-25. [Abstract]; At the indicated concentrations. Cell viability was assessed using CellTiter-Glo (day 7). Data represent percentage NVP-2/AZD4573–treated viable cells compared with vehicle control.

: AZD4573 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Apr 7;31(1):107485. [Abstract]; Survival analysis of atuveciclib and AZD4573 (20 mg/kg, i.p.)-treated cohorts versus vehicle control.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

Biological Activity
Purity & Documentation
References
Customer Review

Description

AZD4573 is a potent and highly selective CDK9 inhibitor (IC₅₀ of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies^[1].

IC₅₀ & Target^[1]

CDK9

4 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	8.29 nM Compound: AZD4573	Inhibition of cell viability in mouse 4T1 cells incubated for 4 days by WST-8 assay Inhibition of cell viability in mouse 4T1 cells incubated for 4 days by WST-8 assay	[PMID: 38885173]
BT-549	IC₅₀	9.57 nM Compound: AZD4573	Inhibition of cell viability in human BT-549 cells incubated for 4 days by WST-8 assay Inhibition of cell viability in human BT-549 cells incubated for 4 days by WST-8 assay	[PMID: 38885173]
MDA-MB-468	IC₅₀	13.57 nM Compound: AZD4573	Inhibition of cell viability in human MDA-MB-468 cells incubated for 4 days by WST-8 assay Inhibition of cell viability in human MDA-MB-468 cells incubated for 4 days by WST-8 assay	[PMID: 38885173]
MM1.S	IC₅₀	6.03 nM Compound: AZD4573	Inhibition of cell viability in human MM1.S cells incubated for 4 days by WST-8 assay Inhibition of cell viability in human MM1.S cells incubated for 4 days by WST-8 assay	[PMID: 38885173]
OPM-2	GI₅₀	23 nM Compound: 16; AZD-4573	Growth inhibition of human OPM-2 cells incubated for 24 hrs Growth inhibition of human OPM-2 cells incubated for 24 hrs	[PMID: 32866383]
T-cell	IC₅₀	< 4 nM Compound: 54; AZD-4573	Inhibition of CDK9/Cyclin T (unknown origin) in presence of ATP by Kinomescan assay Inhibition of CDK9/Cyclin T (unknown origin) in presence of ATP by Kinomescan assay	[PMID: 35485642]

In Vitro

Short-term treatment with AZD4573 led to a rapid dose- and time-dependent decrease in cellular pSer2-RNAPII, resulting in activation of caspase 3 and cell apoptosis in a broad range of haematological cancer cell lines (e.g. caspase activation EC₅₀ 13.7 nM in an acute myeloid leukemia model MV4-11) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AZD4573 exhibits a short half-life in multiple species (less than one hour in rat, dog and monkey) and good solubility for intravenous administration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

429.94

Formula

C₂₂H₂₈ClN₅O₂

CAS No.

2057509-72-3

Appearance

Solid

Color

White to off-white

SMILES

ClC1=CN=C(NC([C@H]2CCC[C@@H](NC(C)=O)C2)=O)C=C1C3=C(CC(C)(C)C4)N4N=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (116.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3259 mL	11.6295 mL	23.2591 mL
5 mM	0.4652 mL	2.3259 mL	4.6518 mL
10 mM	0.2326 mL	1.1630 mL	2.3259 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (276 KB) SDS (254 KB)

COA (252 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Bernard Barlaam, et al. Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies. Cancer Research. July 2018. 78(13): Supplement.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3259 mL	11.6295 mL	23.2591 mL	58.1476 mL
	5 mM	0.4652 mL	2.3259 mL	4.6518 mL	11.6295 mL
	10 mM	0.2326 mL	1.1630 mL	2.3259 mL	5.8148 mL
	15 mM	0.1551 mL	0.7753 mL	1.5506 mL	3.8765 mL
	20 mM	0.1163 mL	0.5815 mL	1.1630 mL	2.9074 mL
	25 mM	0.0930 mL	0.4652 mL	0.9304 mL	2.3259 mL
	30 mM	0.0775 mL	0.3877 mL	0.7753 mL	1.9383 mL
	40 mM	0.0581 mL	0.2907 mL	0.5815 mL	1.4537 mL
	50 mM	0.0465 mL	0.2326 mL	0.4652 mL	1.1630 mL
	60 mM	0.0388 mL	0.1938 mL	0.3877 mL	0.9691 mL
	80 mM	0.0291 mL	0.1454 mL	0.2907 mL	0.7268 mL
	100 mM	0.0233 mL	0.1163 mL	0.2326 mL	0.5815 mL

AZD4573 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AZD45732057509-72-3AZD 4573AZD-4573CDKCyclin dependent kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

AZD4573

Customer Review

AZD4573 Related Antibodies

14 Publications Citing Use of MCE AZD4573

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

AZD4573 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD4573 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report